

Honorary Editor: Dr. Tejas V. Patel Interventional Cardiologist



Dear Friends,

Transcatheter aortic valve replacement (TAVR)/ Transcatheter aortic valve implantation (TAVI) has matured into an accepted mainstay treatment option for patients with severe symptomatic aortic valve stenosis (AS) across the whole spectrum of risk. The advances in the interventional treatment of AS has raised the question of which patients with severe AS should still be referred to surgery. The myriad of clinical permutations does not allow providing a single, uniform treatment strategy for all patients. Rather, the advent of TAVI along with established surgical aortic valve replacement (SAVR) fundamentally enforces the role of the multidisciplinary heart team for decisionmaking recommendations.




Management of Aortic Stenosis & TAVR / TAVI

Introduction

Transcatheter aortic valve implantation (TAVI) has been directly compared with surgical aortic valve replacement (SAVR) in a series of randomized clinical trials across the entire spectrum of surgical risk. Across these trials, TAVI has consistently been associated with clinical outcomes better or comparable to SAVR in terms of all-cause death and stroke throughout longest available follow-up (Figure:1).

In a meta-analysis including seven landmark trials. TAVI was associated with a modest reduction in all-cause death and stroke throughout 2 years In a meta-analysis including seven landmark trials, TAVI was associated with a modest reduction in all-cause death and stroke throughout 2 years irrespective of surgical risk and type of transcatheter heart valve (THV) system, a difference that was apparent in patients allocated to transfemoral TAVI. These excellent outcomes, albeit still mid-term, have led to a paradigm shift in the management of patients with severe aortic valve stenosis (AS) by establishing a less-invasive treatment that allows for more rapid recovery while providing similar clinical benefits as the previous gold standard SAVR.

Figure: 1 Short and long-term outcomes of major randomized clinical trials



Cardiologists

Dr. Vipul Kapoor (M) +91-98240 99848 Dr. Urmil Shah (M) +91-98250 66939 Dr. Tejas V. Patel (M) +91-89403 05130 (M) +91-98250 30111 Dr. Hemang Baxi Dr. Hiren Kevadiva (M) +91-98254 65205 Dr. Anish Chandarana (M) +91-98250 96922 Dr. Gunvant Patel (M) +91-98240 61266 Dr. Ajay Naik (M) +91-98250 82666 Dr. Keyur Parikh (M) +91-98250 26999 (M) +91-99250 45780 Dr. Satya Gupta Dr. Milan Chaq (M) +91-98240 22107

Congenital & Structural Heart Disease Specialist

Dr. Kashyap Sheth (M) +91-99246 12288 Dr. Milan Chaq

(M) +91-98240 22107

Cardiothoracic & Vascular Surgeons

Dr. Dhiren Shah (M) +91-98255 75933 (M) +91-90991 11133 Dr. Dhaval Naik Dr. Amit Chandan (M) +91-96990 84097 (M) +91-99142 81008 Dr. Kishore Gupta (M) +91-73531 65955 Dr. Nikunj Vyas

Paediatric & Structural Heart Surgeons (M) +91-98250 44502 Dr. Shaunak Shah

> Cardiovascular, Thoracic & Thoracoscopic Surgeon

Dr. Pranav Modi (M) +91-99240 84700

Cardiac Anaesthetists

Dr. Niren Bhavsar (M) +91-98795 71917 Dr. Hiren Dholakia (M) +91-95863 75818 Dr. Chintan Sheth (M) +91-91732 04454

Cardiac Electrophysiologist

Dr. Ajay Naik (M) +91-98250 82666 Dr. Hiren Kevadiya (M) +91-98254 65205

Neonatologist and Paediatric Intensivest

Dr. Amit Chitaliya (M) +91-90999 87400







GUIDELINES

As a result, current European and US guidelines for the management of valvular heart disease consider transfemoral TAVI and SAVR both Class I recommendations for the majority of patients with severe, symptomatic AS.

Guideline recommendations choice of surgical aortic valve replacement vs. transcatheter aortic valve implantation for whom a bioprosthesis is appropriate

Recommendations	TAVI		SAVR	
Recommendations	Classe	Levelb	Classe	Levelb
Symptomatic and asymptomatic patients with severe A5 and any indication for AVR who are C65 years of				
age or have a life expectancy over 20 years			1	Α
Symptomatic patient with severe AS who are 65 80 years of age and have no anatomical contraindication				
to transferroral TAVI	1	A	1	A
Symptomatic patient with several AS who are :80 years of age or younger patients with a life expectancy				
:10years and no anatomic contraindication to transfernoral I/I/VI	1	۸	Ila	Α
Asymptotic patients with sever AS and an LVLF <50 who are 65 80 years of age and have no anatomic				
contraindication to transfemoral IAVI	1	B NR	1	B NR
Asymptotic patients with sever AS and an abnormal exercise test, very severe AS, capid progression, or an				
elevated UNP			1	B NR
Patient with an indication for AVR but vascular anatomy or other factor are not suitable for transfernoral				
TAVI			1	A
Symptomatic patients of any age with severe A5 and a high or prohibitive surgical risk (estimated life				
expectancy >12 months)	1	A		
2021 ESC/EACTs Guidelines for the Management of Valvular Heart Disease				•
Younger (5 years)patients who are low risk for Surgery (STS PROM/LuroScore II<4%), or patients who</td <td></td> <td></td> <td></td> <td>1</td>				1
are operable and unsultable for transfemoral TAVI			1	В
Older(+/5years)patients, or in those who are high risk(SIS PROM). EuroScore (I>8%),or unsuitable for				
surgery	1	A.		
Remaining patients according to individual clinical, anatomical, and procedural characteristics				
	1	B	1	U

2020 ACC/AHA Guidelines for the management of Valvular Heart Disease

The decision is usually made by local heart teams taking into consideration multiple and complex clinical and anatomical factors.

	Favours SAVR		Favours TAVI	
Age	65	75	85	
Surgical risk	Low	Intermediate	High - Prohibitive	
railty	Low	Moderate	Severe	
alve morphology	Unfavourable	Intermediate	Favourable	
emoral access	Unfavourable	Intermediate	Favourable	
Concomitant valve lisease	Severe AR Severe primary MR Severe TR	Severe secondary MR Moderate/severe MS Moderate AR/MR/TR	Mild AR/MR/MS/TR	
Coronary artery isease	3-vessel disease and SYNTAX>22 LM disease and SYNTAX>32	• 3-vessel disease and SYNTAX≤22 • LM disease and SYNTAX≤32	1 or 2-vessel disease LM disease and SYNTAX≤2	
Other factors	Aortic disease requiring surgery Septal hypertrophy requiring surge Active endocarditis	ery	Porcelain aorta Previous cardiac surgery Previous chest irradiation Chest malformation Multiple comorbidities	






LIFETIME MANAGEMENT

As TAVI is expanding to younger and low-risk patients with longer life expectancy, it becomes increasingly important to anticipate lifetime management looking beyond the first 10–15 years after the index procedure and prospectively considering subsequent aortic valve replacement strategies. Various treatment strategies can be considered depending on the patient's life expectancy (Figure:2); however, as there is no robust evidence supporting any of the strategies, it is important to regularly update available evidence and recognize the uncertainties that exist for

Figure: 2 Short and long-term outcomes of major randomized clinical trials




TAVR/TAVI VALVES

There are 2 types of TAVI / TAVR Valves: (i) Self-expanding valves (II) Balloon expandable valves


Self-expanding
Evolut Valve system

Self-expanding
Evolution of the self-decimate of the self-de



'Which patients with severe AS should be referred to TAVI or surgery (SAVR)?' is an evolving clinical question in the management of patients with severe AS that has arisen with the advent of TAVI and its reproducible, excellent outcomes. Anatomical and clinical factors, related to TAVI and SAVR, and lifetime management strategies now take center stage in the decision-making process. The multidisciplinary heart team plays a pivotal role to provide an optimal treatment recommendation in a shared decision-making process for individual patients.

Heart Team Approach







Marengo CIMS Hospital, Ahmedabad

INSTITUTE OF CARDIAC SCIENCES

One-stop solution for any cardiac surgery.

Pioneer in Gujarat, India







MINIMALI

LUNG ECN TRANSPLANT

MINIMALLY
INVASIVE CARDIAC
SURGERY (MICS)

TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)

- First in Gujarat in Heart, Lungs & ECMO, and First in India in TAVI
- Only & first centre for paediatric cardiac surgery in private setup
- Performing more than 1000 cases annually
- Experience of 25000 cardiac surgeries
- Multi disciplinary approach





One of India's largest team of Heart Care Experts

TOP ROW LEFT TO RIGHT: Dr. Vipul Ahir | Dhanyata Dholakia | Dr. Chintan Sheth | Dr. Niren Bhavsar | Dr. Nikunj Vyas
Dr. Shaunak Shah | Dr. Dhiren Shah | Dr. Dhaval Naik | Dr. Amit Chandan | Dr. Pranav Modi | Dr. Kishore Gupta
Dr. Hiren Dholakia | Ulhas Padiyar | Akash Raiawat | Dr. Gunyant Patel

BOTTOM ROW LEFT TO RIGHT: Dr. Tejas V. Patel | Dr. Satya Gupta | Dr. Urmil Shah | Dr. Anish Chandarana Dr. Keyur Parikh | Dr. Milan Chag | Dr. Ajay Naik | Dr. Hemang Baxi | Dr. Hiren Kevadiya | Dr. Vipul Kapoor | Dr. Kashyap Sheth

1827

One of the highest coronary angioplasties and stenting (January to December 2022)

98% Successful Hospital Outcome
Highest Number in Gujarat

4th Cathlab Arriving Soon



1000+
Open Heart Surgeries

(January to December 2022)






Marengo CIMS Hospital, Ahmedabad

INSTITUTE OF CARDIAC SCIENCES

THE MOST TRUSTED CARDIAC TEAM



RECORD BREAKING

Heart Surgeries, Heart Transplant, Angioplasty, TAVI, Pacemaker Devices in Recent Times with Full Safety

A CENTRE OF EXCELLENCE FOR TOTAL HEART CARE

- TAVR (Transcatheter Aortic Valve Implantation). 29 Successful TAVR with 100% in hospital success
- Aortic Aneurysm and Dissection Endovascular Interventions TEVAR & EVAR
- Heart Transplant: Only Centre in Gujarat with Successful Heart Transplant Program
- PAMI (Primary Angioplasty in Myocardial Infarction) since year 2000
- Complex and High Risk Procedures with FFR, OCT, IVUS, IVL, ROTABLATION as well as Cardiac MR & Cardiac CT for Complex Angioplasty
- Structural Heart Intervention Program
- Congenital Heart Disease / Structural Heart disease All Surgeries and Devices
- Arrhythmia and Heart Failure with Full Cardiac Device Program
- Leading center of EP Studies, RF ablation therapy and 3D mapping for Complex arrhythmia management.
- MICS (Minimally Invasive Cardiac Surgery) and Routine Surgeries: Total Arterial (BIMA) Bypass, Valve Replacement, Aortic Aneurysm and Dissection
- Peripheral & Carotid Intervention Program
- · Intravascular Lithotripsy, Bioabsorbable Stents/Scaffolds





Marengo CIMS Hospital, Ahmedabad



World-class Infrastructure | State-of-the-art Technologies | Better Facilities | Specialized and Experienced Team of Experts

- ✓ First Successful Heart and Lung Transplant of Gujarat
- ✓ Paediatric Bone Marrow Transplant Unit for Thalassemia First in Gujarat
- ✓ TAVR/TAVI First in Gujarat
- ✓ Digitized Ots and ICUs for better patient care First in Gujarat
- ✓ First in Asia Pacific to set up Elekta Versa HD for cancer radiation treatment
- ✓ MRI Signa Explorer First in Gujarat
- ✓ Carl Zeiss Pentero 900 Microscope First in Gujarat
- ✓ One of the first ECMO (Extracorporsal Membrane Oxygenation) machine in Gujarat for patients with cardio respiratory failure
- ✓ The First exclusive Trauma Centre in Western India to have ATLS and BLS protocol based management
 of trauma
- ✓ State-of-the-art Pentax First in Gujarat HD EUS / EBUS (J 10 Series) with HD Optivista plus processor for better diagnosis
- ✓ First installation of EPIQ Cvxi in Ahmedabad-premium interventional cardiology ultrasound system
- ✓ ERBE CPYO[™]2 for therapeutic and diagnostic applications in pulmonology
- ✓ First Specialised Transplant Unit in Private Sector in Gujarat













WEDNESDAY, 7th JUNE, 2023

HIGHEST NUMBER IN GUJARAT

100% SUCCESSFUL HOSPITAL OUTCOMES

INDIA'S BEST HEART CARE EXPERTS

LEADER ACROSS INDIA IN TRANSPLANTS

HEART TRANSPLANT

JUNE 06, 2023



LIVER TRANSPLANT

JUNE 04, 2023





Kidney Transplant



Paediatric BMT



Lung Transplant





Healthy Heart Registered under RNI No. GUJENG/2008/28043

Published on 5th of every month

Permitted to post at PSO, Ahmedabad-380002 on the 12th to 17th of every month under Postal Registration No. GAMC-1725/2021-23 issued by SSP Ahmedabad valid upto 31st December, 2023 Licence to Post Without Prepayment No. PMG/NG/055/2021-23 valid upto 31st December, 2023

If undelivered please return to:

Marengo CIMS Hospital,

Nr. Shukan Mall, Off Science City Road,

Sola, Ahmedabad-380060.

Call: 1800 309 9999

Subscribe "Healthy Heart": Get your "Healthy Heart", the information of the latest medical updates only ₹ 60/- for one year. To subscribe pay ₹ 60/- in cash or cheque/DD at CIMS Hospital Pvt. Ltd. Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad-380060. Phone: +91-79-4805 2823. Cheque/DD should be in the name of: "CIMS Hospital Pvt. Ltd."

Please provide your complete postal address with pincode, phone, mobile and email id along with your subscription



DO NOT MISS

20th Annual Scientific Symposium | 29th Year of Academics

SUPER EARLY BIRD PRIZE*

Register for JIC 2024

UPTO JUNE, 2023

And Get an Attractive Prize (*For the First 500 Registrants Only)

For MD Physicians
₹ 2,000/- Only

For MD Students
₹ 1,000/- Only

Marengo CIMS Hospital : Regd Office: Plot No.67/1, Opp. Panchamrut Bunglows, Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad - 380060.

Ph. : +91-79-2771 2771-72 | 4805 | | | |

CIMS Hospital Pvt. Ltd. | CIN: U85110GJ2001PTC039962 | marengocims.info@marengoasia.com | www.cims.org

Printed, Published and Edited by Dr. Keyur Parikh on behalf of the Marengo CIMS Hospital Printed at Hari Om Printery, 15/1, Nagori Estate, Opp. E.S.I. Dispensary, Dudheshwar Road, Ahmedabad-380004. Published from Marengo CIMS Hospital, Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad-380060.